1 citations
,
June 2013 in “Annals of the Rheumatic Diseases” This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.
June 2013 in “Annals of the rheumatic diseases” This study concluded that while methotrexate-related adverse events were infrequent in early rheumatoid arthritis patients taking adalimumab, some increased with higher methotrexate doses, suggesting use of the lowest effective dose.
June 2017 in “Poster presentations” In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.
February 2016 in “Annals of the Rheumatic Diseases” In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.
This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.
